All In Biotech

Drug Trial Radar · NCT07141030

Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal Function

To Assess the Pharmacokinetic (PK) Differences of GZR18 Injection Between Subjects With Renal Impairment and Those With Normal Renal Function, Providing a Basis for Establishing a Clinical Dosing Regimen for Patients With Renal Impairment

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Apr 11, 2025

Primary completion

Oct 20, 2025

Study completion Oct 20, 2025

Sponsor

Lead sponsor
Gan & Lee Pharmaceuticals.Industry
Sponsor type
Industry
First posted
Aug 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study adopts a multicenter, single-dose, open-label, and parallel design, which is aimed at assessing the PK and safety profiles of GZR18 Injection in subjects with normal renal function and those with mild, moderate or severe renal impairment. The study duration for each subject in this study is up to 50 days, including a screening period of up to 14 days (Day-14 to Day-1), an 8-day dosing/observation period (Day 1 to Day 8), and a 28-day follow-up period (Day 9 to Day 36).

Conditions

  • Obesity/Overweight

Interventions

  • GZR18 injectionDrug

    GZR18 injection:3mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax:Maximum plasma concentrationTime frame: through study completion, an average of 36 days
  2. AUC0-last:Area under the plasma concentration-time curve at 0 h to last observation time-point after a single dose.Time frame: through study completion, an average of 36 days
  3. AUC0-inf:Area under the plasma concentration-time curve at 0 h to infinity after a single dose.Time frame: through study completion, an average of 36 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Gan & Lee Pharmaceuticals

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.